Collegium Pharmaceutical, Inc. (COLL): Price and Financial Metrics

Collegium Pharmaceutical, Inc. (COLL)

Today's Latest Price: $23.75 USD

2.07 (9.55%)

Updated Feb 28 12:00am

Add COLL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

COLL Stock Summary

  • With a year-over-year growth in debt of 90.1%, Collegium Pharmaceutical Inc's debt growth rate surpasses 85.31% of about US stocks.
  • As for revenue growth, note that COLL's revenue has grown 35.88% over the past 12 months; that beats the revenue growth of 85.73% of US companies in our set.
  • The volatility of Collegium Pharmaceutical Inc's share price is greater than that of 89.97% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Collegium Pharmaceutical Inc, a group of peers worth examining would be CDXC, SREV, SIEN, TEDU, and OFIX.
  • Visit COLL's SEC page to see the company's official filings. To visit the company's web site, go to
COLL Daily Price Range
COLL 52-Week Price Range

COLL Stock Price Chart More Charts

COLL Price/Volume Stats

Current price $23.75 52-week high $25.59
Prev. close $21.68 52-week low $10.01
Day low $21.58 Volume 1,359,300
Day high $24.55 Avg. volume 768,930
50-day MA $21.85 Dividend yield N/A
200-day MA $15.36 Market Cap 796.27M

Collegium Pharmaceutical, Inc. (COLL) Company Bio

Collegium Pharmaceuticals is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain and other diseases. The company was founded in 2002 and is based in Canton, Massachusetts.

COLL Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$23.75$4.44 -80%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Collegium Pharmaceutical Inc. To summarize, we found that Collegium Pharmaceutical Inc ranked in the 17th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Collegium Pharmaceutical Inc ended up being:

  • The company's debt burden, as measured by earnings divided by interest payments, is -2.69 -- which is good for besting only 17.13% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The company's compound free cash flow growth rate over the past 1.25 years comes in at -0.15%; that's greater than just 12.6% of US stocks we're applying DCF forecasting to.
  • The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than only 11.42% of the free cash flow producing stocks we're observing.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Collegium Pharmaceutical Inc? See AMPH, HAE, CNMD, GMED, and QGEN.

COLL Latest News Stream

Event/Time News Detail
Loading, please wait...

COLL Latest Social Stream

Loading social stream, please wait...

View Full COLL Social Stream

COLL Price Returns

1-mo 18.81%
3-mo 9.30%
6-mo 105.09%
1-year 29.85%
3-year 70.86%
5-year N/A
YTD 15.40%
2019 19.86%
2018 -6.99%
2017 18.56%
2016 -43.38%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5965 seconds.